Predictive Diagnosis of Ulcero-Necrotizing EnteroColitis in Premature Babies Using an Artificial Intelligence Approach Based on Early Analysis of the Fecal Microbiota

Recruiting N/A Interventional Study
Necrotizing Enterocolitis (NEC) Healthy Control
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
Up to 1 Day
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
1,000 (estimated)
Sponsor
University Hospital, Clermont-Ferrand · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Prematurity affects around 7% of births in France. Necrotizing enterocolitis (NEC) is a dreaded digestive complication. It is responsible for a mortality rate ranging from 15 to 40%, a rate that has remained stable in recent years, and for medium- and long-term digestive and neurodevelopmental morbidity. Its onset is unpredictable and sudden, usually between 10 and 20 days of life, and requires i…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Child born prematurely (i.e. before 34 weeks of amenorrhea) in one of participating university hospitals and hospitalized in neonatal intensive care units of the AURA region's university hospitals * Child born outside CHU and transferred before 24h of life to the neonatal inte…
Contacts

Lise Laclautre

334.73.754.963

promo_interne_drci@chu-clermontferrand.fr

CONTACT